The use of azathioprine in severe adult atopic eczema
Article first published online: 29 SEP 2006
Journal of the European Academy of Dermatology and Venereology
Volume 11, Issue 2, pages 137–140, September 1998
How to Cite
Buckley, D.A., Baldwin, P. and Rogers, S. (1998), The use of azathioprine in severe adult atopic eczema. Journal of the European Academy of Dermatology and Venereology, 11: 137–140. doi: 10.1111/j.1468-3083.1998.tb00766.x
- Issue published online: 29 SEP 2006
- Article first published online: 29 SEP 2006
- Atopic eczema;
- Systemic therapy
To evaluate the use of azathioprine in the treatment of severe adult atopic eczema and review the relevant literature.
Effective treatment of severe adult atopic eczema may necessitate the use of agents such as systemic steroids, PUVA or cyclosporin, which are associated with significant morbidity. Azathioprine is an effective alternative which can induce disease remission and may be less toxic.
Ten patients treated with azathioprine 0.7–2.5 mg/kg per day for a minimum period of 12 months were evaluated in a retrospective follow-up study.
Clearance or marked improvement was noted in eight patients; three of these later became refractory to the drug. Side-effects were few and were well-tolerated. One patient was found to have lymphoma 8 months after stopping treatment.
Azathioprine is an effective and cheaper alternative to cyclosporin in the treatment of severe adult atopic eczema. Its long-term toxicity remains unclear.